Clinical efficacy of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis

被引：0
|
作者：
Martinelli, G
Mingrone, W
Alietti, A
Ferrucci, F
Cocorocchio, E
Peccatori, F
Cinieri, S
Corsini, C
Zucca, E
Bertolini, F
机构：
[1] European Inst Oncol, Milan, Italy
[2] Oncol Inst So Switzerland, Bellinzona, Switzerland
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
F13
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma
    Wang, Yu
    Man, Qi-hang
    Li, Chao
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2023, 39 (05) : 1243 - 1248
  • [22] Thalidomide-induced hypercoagulability in multiple myeloma (MM).
    Zangari, M
    Anaissie, E
    Desikan, R
    Badros, A
    Morris, C
    Munshi, N
    Gopal, AV
    Fink, L
    Spoon, D
    Tricot, G
    Barlogie, B
    BLOOD, 2000, 96 (11) : 296B - 296B
  • [23] Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS Register
    Gioia, D.
    Cilloni, D.
    Salvi, F.
    Audisio, E.
    Boccomini, C.
    Bonferroni, M.
    Cametti, G.
    Ciravegna, G.
    Darbesio, A.
    Dellacasa, C.
    Ferrero, D.
    Freilone, R.
    Gatto, S.
    Lunghi, M.
    Gallamini, A.
    Gaidano, G.
    Girotto, M.
    Marmont, F.
    Marinone, C.
    Messa, E.
    Perticone, S.
    Pollio, B.
    Tonso, A.
    Saglio, G.
    Levis, A.
    LEUKEMIA RESEARCH, 2007, 31 : S41 - S42
  • [24] EFFICACY AND SAFETY OF THALIDOMIDE IN THE TREATMENT OF MULTIPLE MYELOMA
    Warzocha, Krzysztof
    Kraj, Maria
    Poglod, Ryszard
    Szpila, Tomasz
    Mendek-Czajkowska, Ewa
    Chelstowska, Monika
    Tronina, Renata Hagedorna
    ACTA POLONIAE PHARMACEUTICA, 2008, 65 (06): : 771 - 774
  • [25] Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS)
    Valent, Peter
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2009, 2 : 13 - 17
  • [26] Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS)
    Peter Valent
    memo - Magazine of European Medical Oncology, 2009, 2 (Suppl 1) : 13 - 17
  • [27] Clinical Experience of Decitabine in Elderly Patients with Myelodysplastic Syndromes (MDS)
    Geils, George F., Jr.
    BLOOD, 2009, 114 (22) : 1092 - 1092
  • [28] Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide.
    Badros, A
    Zangari, M
    Bodenner, D
    Siegel, E
    Spoon, D
    Toor, A
    Desikan, R
    Arnold, E
    Anaissie, E
    Zeldis, J
    Tricot, G
    Barlogie, B
    BLOOD, 2000, 96 (11) : 285B - 285B
  • [29] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
    Kenealy, Melita K.
    Seymour, John F.
    Linda, Cowan
    Milner, Alvin
    Giri, Pratyush
    Ho, Shir-Jing
    Benson, Warwick
    Nicol, Andrew
    Campbell, Philip
    Prosser, Ian
    Underhill, Craig
    Cunningham, Ilona
    Mills, Anthony K.
    Szer, Jeffrey
    Presgrave, Peter
    Filshie, Robin
    BLOOD, 2009, 114 (22) : 695 - 695
  • [30] Efficacy of azacitidine for TP53-mutated myelodysplastic syndromes (MDS).
    Nannya, Yasuhito
    Takeda, June
    Sato, Shinya
    Shiraishi, Yuichi
    Yoshida, Kenichi
    Shiozawa, Yusuke
    Makishima, Hideki
    Nakao, Shinji
    Ohyashiki, Kazuma
    Miyazaki, Yasushi
    Naoe, Tomoki
    Miyano, Satoru
    Ogawa, Seishi
    CANCER SCIENCE, 2018, 109 : 423 - 423
12345